NCT07428499Phase 3Recruiting

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Study sponsor: ADARx Pharmaceuticals, Inc. · ADRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-06-30Estimated
Enrollment · participants90Estimated
Source updated2026-09-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source